<DOC>
	<DOCNO>NCT01492361</DOCNO>
	<brief_summary>AMR101 ( icosapent ethyl [ ethyl-EPA ] ) highly purify ethyl ester eicosapentaenoic acid ( EPA ) develop Amarin Pharma Inc. treatment hypertriglyceridemia . The purpose study evaluate whether drug , combine statin therapy , superior statin therapy alone , use prevention reduce long-term cardiovascular event high-risk patient mixed dyslipidemia .</brief_summary>
	<brief_title>A Study AMR101 Evaluate Its Ability Reduce Cardiovascular Events High Risk Patients With Hypertriglyceridemia Statin . The Primary Objective Evaluate Effect 4 g/Day AMR101 Preventing Occurrence First Major Cardiovascular Event .</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Eicosapentaenoic acid ethyl ester</mesh_term>
	<criteria>Men nonpregnant sterile woman age 45 old Hypertriglyceridemia On statin therapy least four week Either establish Cardiovascular Disease high risk Cardiovascular Disease Severe heart failure Any lifethreatening disease Cardiovascular Disease Active severe liver disease Hemoglobin A1c &gt; 10.0 % Poorly control hypertension Planned coronary intervention ( stent placement heart bypass ) noncardiac major surgical procedure Known familial lipoprotein lipase deficiency ( Fredrickson Type I ) , apolipoprotein CII deficiency , familial dysbetalipoproteinemia ( Fredrickson Type III ) Known hypersensitivity study product , fish and/or shellfish , placebo History acute chronic pancreatitis Patients exclude use follow medication : niacin &gt; 200 mg/day fibrates ; omega3 fatty acid medication ; dietary supplement contain omega3 fatty acid ( e.g. , flaxseed oil , fish oil , krill oil , algal oil ) ; bile acid sequestrants</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>Coronary Disease</keyword>
	<keyword>Heart Diseases</keyword>
	<keyword>Acute Coronary Syndrome</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Arteriosclerosis</keyword>
	<keyword>Arterial Occlusive Diseases</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Angina Pectoris</keyword>
	<keyword>Chest Pain</keyword>
	<keyword>Anticholesteremic Agents</keyword>
	<keyword>Hypolipidemic Agents</keyword>
	<keyword>Lipid Regulating Agents</keyword>
	<keyword>hypertriglyceridemia</keyword>
	<keyword>omega-3 fatty acid</keyword>
	<keyword>statin</keyword>
	<keyword>triglyceride</keyword>
	<keyword>EPA</keyword>
	<keyword>docosahexaenoic acid</keyword>
	<keyword>fish</keyword>
	<keyword>fatty acid</keyword>
	<keyword>fibrates</keyword>
	<keyword>niacin</keyword>
	<keyword>lipid</keyword>
	<keyword>lipoprotein</keyword>
	<keyword>atorvastatin</keyword>
	<keyword>Lovaza</keyword>
	<keyword>simvastatin</keyword>
	<keyword>lovastatin</keyword>
	<keyword>pravastatin</keyword>
	<keyword>fluvastatin</keyword>
	<keyword>rosuvastatin</keyword>
	<keyword>Trilipix</keyword>
	<keyword>Vytorin</keyword>
	<keyword>Simcor</keyword>
	<keyword>ezetimibe</keyword>
	<keyword>Zetia</keyword>
	<keyword>ethyl-EPA</keyword>
	<keyword>ethyl icosapentate</keyword>
	<keyword>Crestor</keyword>
	<keyword>Zocor</keyword>
	<keyword>Lipitor</keyword>
	<keyword>LDL</keyword>
	<keyword>HDL</keyword>
	<keyword>cholesterol</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>AMR101</keyword>
	<keyword>Cardiovascular Disease , Unspecified</keyword>
	<keyword>VASCEPA</keyword>
	<keyword>icosapent ethyl</keyword>
</DOC>